Updated:
X-Chem
X-Chem is a drug-discovery platform led by CEO John P. McDevitt, offering DNA-encoded library technology and partnerships with major pharmaceutical...
X-Chem
X-Chem was founded in 2000 out of research from the University of Chicago and has grown into a leading provider of DNA-encoded library (DEL) technology for drug discovery. The company is headquartered in Waltham, Massachusetts, and operates as a private contract research and technology platform. It was originally spun out from the University of Chicago with seed funding from venture firm Flagship Pioneering (per Flagship Pioneering website). The firm's strategy centers on its proprietary DEL platform, which enables screening of vast compound libraries against biological targets. X-Chem focuses on early-stage drug discovery across therapeutic areas including oncology, inflammation, immunology, and infectious disease. It has disclosed partnerships with major pharmaceutical companies such as Pfizer, Novartis, and Genentech (per public filings, 2022). The company also invests in its own pipeline of internally discovered assets, occasionally spinning out or licensing candidates for later-stage development. Geographically, its operations are primarily in the United States. X-Chem employs roughly 200 scientists and staff, as per its public profile. The firm has raised venture funding from life sciences investors including Flagship Pioneering and Atlas Venture. In recent years, it has focused on expanding its internal discovery engine and deepening partnerships. May 2024: X-Chem announced a partnership with Pfizer to discover novel small-molecule drugs using the DEL platform (per press release). The company maintains a broad portfolio of active collaborations and has not disclosed plans for additional external capital. A structural differentiator is X-Chem's dual model: it both serves as a CRO for major pharma and builds its own internal pipeline. This hybrid structure means it generates revenue from partnerships while retaining upside on internally developed assets. The firm's DEL technology is a key enabler—the library size and quality give it a competitive edge over other drug-discovery platforms in its sector.
General information
Firm type
Asset Manager
Year founded
2000
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Waltham
Corporate office
Waltham, MA, United States
Principals
John P. McDevitt
Chief Executive Officer
Jeffrey A. Hill
President
Sector focus
Frequently asked questions
Who runs investment decisions at X-Chem?
X-Chem is a drug-discovery company, not a family office or investment firm. Strategic and operational decisions are made by CEO John P. McDevitt and President Jeffrey A. Hill, along with the board of directors representing venture investors Flagship Pioneering and Atlas Venture.
How does X-Chem generate revenue?
X-Chem generates revenue primarily through fee-for-service contracts with large pharmaceutical companies such as Pfizer, Novartis, and Genentech. Additionally, it earns success-based milestone payments and royalties from candidates advanced through its partnerships, and retains value on internally discovered assets.
What is X-Chem's DEL platform and how large is its library?
X-Chem's DEL (DNA-encoded library) platform screens billions of compounds against therapeutic targets. The firm's library reportedly exceeds 250 billion compounds, making it one of the largest in the industry. This enables rapid identification of small-molecule leads for difficult targets.
Is X-Chem a contract research organization or a biotech company?
X-Chem operates as a hybrid: it functions as a contract research organization by performing fee-for-service work for pharma partners, but also runs its own internal discovery programs. It can spin out or license internally developed candidates, giving it characteristics of a biotech.
Does X-Chem accept external capital from investors?
X-Chem has raised venture capital from investors including Flagship Pioneering and Atlas Venture. The company is privately held and does not publicly disclose its capital structure. There is no public indication it seeks additional external investment as of late 2024.
What therapeutic areas does X-Chem focus on?
X-Chem's platform is primarily aimed at oncology, inflammation, immunology, and infectious disease. Its technology is target-agnostic, but disclosed partnerships and pipeline assets cluster around these areas.
How is X-Chem related to the University of Chicago?
X-Chem was originally spun out from research at the University of Chicago in 2000. The university holds no current public disclosure of ongoing ties or equity stake.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: